Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals has initiated a phase I study in the US to evaluate the human safety and pharmacology of ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus.
Subscribe to our email newsletter
Earlier this month, Alnylam initiated its first phase I study in Europe and received clearance of its investigational new drug application by the FDA.
Respiratory syncytial virus (RSV) is a highly contagious virus that causes infections in both the upper and lower respiratory tract. RSV infects nearly every child at least once by the age of two years and is a major cause of hospitalization due to respiratory infection in children and people with compromised immune systems.
“ALN-RSV01 has the potential to be a novel approach for the treatment of RSV, an area where an effective anti-viral is clearly needed,” said Dr John Maraganore, president and CEO of Alnylam.
RSV infection typically results in cold-like symptoms but can lead to more serious respiratory illness such as croup and pneumonia, bronchiolitis.